Payment overview · 2025
General Payments
$15,958.69
219 reported records · 39 companies
Healthcare provider profile · identity verified
Michael Sauter, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · INDIANA, PA · NPI 1205837051
Verified facts
What the public records show
CMS Open Payments records show Michael Sauter, M.D. received $15,958.69 in general payments during 2025 across 219 reported records.
Eisai Inc. accounted for 50.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Inbrija, Ingrezza, Leqembi, Nurtec Odt.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LEQEMBI as an associated drug or biological on 4686 records involving 1817 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Leqembi by this doctor in 2024.
Eisai Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Leqembi as an associated drug or biological on 28719 records involving 10254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Leqembi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xarelto by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INBRIJA as an associated drug or biological on 4307 records involving 2211 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Inbrija by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MAYZENT as an associated drug or biological on 26 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mayzent by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xcopri by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Gammagard Liquid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $8,010.89 | 50.2% | 19 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $4,109.80 | 25.8% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $602.44 | 3.8% | 43 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $518.21 | 3.2% | 9 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $288.68 | 1.8% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $273.86 | 1.7% | 19 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $251.81 | 1.6% | 16 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $198.34 | 1.2% | 11 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $156.69 | 1.0% | 8 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $137.46 | 0.9% | 7 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $118.98 | 0.8% | 5 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $112.58 | 0.7% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$89.85 | 0.6% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $87.06 | 0.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $85.26 | 0.5% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $83.91 | 0.5% | 5 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $78.56 | 0.5% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $75.70 | 0.5% | 3 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $70.92 | 0.4% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $63.75 | 0.4% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $58.17 | 0.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $46.31 | 0.3% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.96 | 0.3% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $43.77 | 0.3% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $35.16 | 0.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.75 | 0.2% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $31.99 | 0.2% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $29.57 | 0.2% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $24.29 | 0.1% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $23.31 | 0.1% | 1 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $23.07 | 0.1% | 1 | 2025 |
| Life Molecular Imaging Ltd | Unresolved — no canonical attribution shown | $22.25 | 0.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.86 | 0.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $21.48 | 0.1% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.45 | 0.1% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $17.65 | 0.1% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $16.66 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.58 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.66 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for serving as faculty or as a speaker for a medical education program | $6,370.00 | 6 |
| Food and Beverage | $4,368.36 | 205 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,515.45 | 2 |
| Consulting Fee | $1,300.00 | 1 |
| Travel and Lodging | $389.93 | 4 |
| Education | $14.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $8,010.89 | 19 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $4,193.71 | 13 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $518.21 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $450.05 | 35 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $442.34 | 34 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $288.68 | 16 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $251.81 | 16 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $166.61 | 9 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $151.59 | 9 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $147.64 | 8 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $129.92 | 8 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $118.98 | 5 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $117.62 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $107.25 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $100.81 | 9 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $87.06 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $85.26 | 4 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $78.56 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $75.70 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $68.24 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $63.75 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $61.17 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $58.17 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $46.31 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $45.96 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $43.77 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $41.26 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $39.07 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $35.16 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $32.75 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $28.49 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $27.73 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $26.62 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| NEURACEQ Normalized: neuraceq |
Drug | Life Molecular Imaging Ltd | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INBRIJA inbrija |
2025 | Inbrija | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Leqembi leqembi |
2025 | Leqembi | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | LEQEMBI open payments reported associated product |
CMS Open Payments — General Payments 4686 supporting records · 1817 recipient NPIs · example record 1208299730 |
Leqembi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Eisai Inc. Exact reporting entity; no affiliate inference |
2025 | Leqembi open payments reported associated product |
CMS Open Payments — General Payments 28719 supporting records · 10254 recipient NPIs · example record 1244455613 |
Leqembi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | INBRIJA open payments reported associated product |
CMS Open Payments — General Payments 4307 supporting records · 2211 recipient NPIs · example record 1232555387 |
Inbrija · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | MAYZENT open payments reported associated product |
CMS Open Payments — General Payments 26 supporting records · 26 recipient NPIs · example record 1200006493 |
Mayzent · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 344 | 73 |
| Lamotrigine | Lamotrigine | 274 | 43 |
| Gabapentin | Gabapentin | 270 | 60 |
| Memantine Hcl | Memantine Hcl | 225 | 47 |
| Baclofen | Baclofen | 211 | 45 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 198 | 50 |
| Primidone | Primidone | 184 | 36 |
| Atorvastatin Calcium | Atorvastatin Calcium | 160 | 37 |
| Topiramate | Topiramate | 146 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 25 |
| Donepezil Hcl | Donepezil Hcl | 114 | 31 |
| Oxcarbazepine | Oxcarbazepine | 104 | 18 |
| Divalproex Sodium Er | Divalproex Sodium | 71 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 71 | 15 |
| Carbamazepine Er | Carbamazepine | 64 | suppressed |
| Pregabalin | Pregabalin | 63 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 59 | 14 |
| Sodium Chloride | 0.9 % Sodium Chloride | 57 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 56 | 13 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 51 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | suppressed |
| Mirtazapine | Mirtazapine | 47 | suppressed |
| Lisinopril | Lisinopril | 46 | 13 |
| Sertraline Hcl | Sertraline Hcl | 44 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Ingrezza | Valbenazine Tosylate | 40 | suppressed |
| Amantadine | Amantadine Hcl | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | 11 |
| Austedo | Deutetrabenazine | 36 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Austedo Xr | Deutetrabenazine | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Zonisamide | Zonisamide | 32 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 31 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 29 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Entacapone | Entacapone | 24 | suppressed |
| Keppra | Levetiracetam | 24 | suppressed |
| Fingolimod | Fingolimod Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Tegretol Xr | Carbamazepine | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Copaxone | Glatiramer Acetate | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Teriflunomide | Teriflunomide | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Rufinamide | Rufinamide | 18 | suppressed |
| Tegretol | Carbamazepine | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Carbatrol | Carbamazepine | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Inbrija | Levodopa | 13 | suppressed |
| Mayzent | Siponimod | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Dalfampridine Er | Dalfampridine | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Betaseron | Interferon Beta-1b | 11 | suppressed |
| Leqembi | Lecanemab-Irmb | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Xcopri | Cenobamate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15,958.69 · 219 records | Eisai Inc. | AMPYRA, AUSTEDO XR, BOTOX, BRIUMVI, Bafiertam, Briviact, CREXONT, DAYBUE, Fintepla, Gamunex-C, Gocovri, HYQVIA, Hizentra, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, Leqembi, NEURACEQ, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus, PANZYGA, PONVORY, QULIPTA, QUTENZA, REXULTI, Radicava, Rystiggo, SKYCLARYS, SPINRAZA, Symbravo, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, VUMERITY, VYALEV, VYEPTI, VYKAT XR, VYVGART HYTRULO, WAINUA, Xeomin, ZAVZPRET, ZEPOSIA | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Biogen, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error